-
Revista Brasileira de Pesquisas Medicas... Jun 1979A review of the present results of bone-marrow transplantation (B.M.T.) in severe aplastic anaemia is presented. Nowadays, there is little doubt that for patients with... (Review)
Review
A review of the present results of bone-marrow transplantation (B.M.T.) in severe aplastic anaemia is presented. Nowadays, there is little doubt that for patients with severe aplastic anaemia the treatment of choice is the B.M.T. provided always that a suitable donor exists. If the patient is fortunate enough to have a normal identical twin, the syngeneic B.M.T. without immunosuppresive conditioning must be performed. This is usually successful, though in some patients failures can be observed due to probable immunological interference. This can be overcome by a new syngeneic B.M.T. preceded by immunosuppression. The usual type of suitable donors is an HLA-identical (including locus D) sibling (allogeneic B.M.T.). Approximately 50% of patients treated in this way can become long-term survivors. The chief complications causing mortality from the allogeneic B.M.T. are graft rejection and graft-versus-host-disease (G.V.H.D.). In order to reduce the graft rejection rate, transfusions from marrow-donor and relatives prior to the transplantation should be avoided. Other probable factor influencing the final outcome of the allogeneic B.M.T. are the interval diagnosis-transplantation, age of the patient, marrow cell dose, the difference of sex between the donor and the recipients and others. Semi-incompatible and incompatible allogeneic B.M.T. are briefly considered.
Topics: Age Factors; Anemia, Aplastic; Blood Transfusion; Bone Marrow Transplantation; Female; Graft Rejection; Graft vs Host Reaction; Histocompatibility; Humans; Immunosuppression Therapy; Male; Sex Factors; Transplantation, Homologous; Transplantation, Isogeneic
PubMed: 42120
DOI: No ID Found -
British Medical Journal Aug 1954
Topics: Anemia; Anemia, Aplastic; Humans; Occupational Diseases; Toluene; Trinitrotoluene
PubMed: 13182236
DOI: 10.1136/bmj.2.4885.430 -
Lancet (London, England) Nov 1967
Topics: Anemia, Aplastic; Erythropoiesis; Female; Humans; Lectins; Lymphocytes; Male
PubMed: 4167529
DOI: 10.1016/s0140-6736(67)90838-0 -
Revue de L'infirmiere Jan 2014Aplastic anaemia is diagnosed on the basis of a clinical and biological examination. Treatment depends on the grade of the severity of the infectious and haemorrhagic...
Aplastic anaemia is diagnosed on the basis of a clinical and biological examination. Treatment depends on the grade of the severity of the infectious and haemorrhagic syndromes. It will be symptomatic and, if possible, curative, thanks to a bone marrow transplant.
Topics: Anemia, Aplastic; Blood Transfusion; Bone Marrow Transplantation; Humans; Immunosuppressive Agents; Severity of Illness Index
PubMed: 24624714
DOI: 10.1016/j.revinf.2013.10.021 -
British Journal of Haematology Apr 2013
Review
Topics: Amino Acid Substitution; Anemia, Aplastic; Female; Hemoglobinuria, Paroxysmal; Humans; Janus Kinase 2; Male; Mutation, Missense
PubMed: 23360357
DOI: 10.1111/bjh.12224 -
European Journal of Haematology.... 1996Agranulocytosis and aplastic anaemia are rare but serious conditions known to be caused by numerous drugs. Most of what is known or suspected about the aetiology is...
Agranulocytosis and aplastic anaemia are rare but serious conditions known to be caused by numerous drugs. Most of what is known or suspected about the aetiology is based on case reports, with only a few formal epidemiological studies that provide quantitative estimates of risk. Updated results have been obtained from a combined analysis of data from 3 case-control studies that used similar methods: the International Agranulocytosis and Aplastic Anemia Study (IAAAS), conducted in Israel and Europe; a study conducted in the northeast US; and a study conducted in Thailand. Totals of 362 cases of agranulocytosis, 454 cases of aplastic anaemia and 6458 controls were included in the analyses. The IAAAS and Thai study were population-based, providing estimates of the incidence of the 2 dyscrasias. The overall annual incidence of agranulocytosis in the ambulatory population was 3.4/10(6) in the IAAAS and 0.8/10(6) in Thailand; by contrast the incidence of aplastic anaemia was 2.0/10(6) in the IAAAS and 4.1/10(6) in Thailand. A total of 21 compounds were significantly associated with an increased risk of agranulocytosis in the IAAAS and US studies. Excess risks ranged from 0.06 to 13 cases/10(6) users/wk; the most strongly associated drugs were procainamide, anti-thyroid drugs and sulphasalazine. An association with drugs that had previously been suspected was also seen in Thailand. The overall aetiologic fractions of agranulocytosis due to drug use were 62% in the IAAAS, 72% in the US and 70% in Thailand. Eleven drugs were significantly associated with an increased risk of aplastic anaemia, with excess risks ranging from 1.4 to 60 cases/10(6) users in a 5-month period. The most strongly associated drugs were penicillamine, gold and carbamazepine. Aetiologic fractions were 27% in the IAAAS, 17% in the US and 2% in Thailand, which paralleled the prevalence of use of associated drugs in the 3 populations. The present results confirm that agranulocytosis is largely a drug-induced disease, with similar proportions accounted for in 3 disparate geographic regions. By contrast, although many of the expected associations were observed for aplastic anaemia, most of the aetiology is not explained by drugs. For all associated drugs, the excess risks are sufficiently low that blood dyscrasias should not figure prominently in the balancing of risks and benefits.
Topics: Agranulocytosis; Anemia, Aplastic; Case-Control Studies; Europe; Humans; Incidence; Israel; Risk Factors
PubMed: 8987237
DOI: 10.1111/j.1600-0609.1996.tb01641.x -
The British Journal of Dermatology Oct 1959
Topics: Anemia; Anemia, Aplastic; Dermatomyositis; Humans
PubMed: 13818636
DOI: 10.1111/j.1365-2133.1959.tb13360.x -
The Journal of the Association of... Mar 2015
Topics: Anemia, Aplastic; Benzoates; Blood Transfusion; Hematologic Agents; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Hydrazines; Immunosuppression Therapy; Opportunistic Infections; Prognosis; Pyrazoles; Secondary Prevention
PubMed: 26529864
DOI: No ID Found -
British Journal of Haematology Sep 2023Aplastic anaemia (AA) is a rare immune-related adverse events (irAEs) after immune checkpoint inhibitors (ICIs) administration with poorly understood incidence and...
Aplastic anaemia (AA) is a rare immune-related adverse events (irAEs) after immune checkpoint inhibitors (ICIs) administration with poorly understood incidence and outcomes. We analysed an electronic health record database of 52 303 ICI-treated patients and found 77 (0.15%) cases of AA, with a median onset of 126 days (interquartile range, 58-363 days). The most used treatment for AA was systemic glucocorticoids 60 (77.9%) and 32 (41.6%) patients were able to resume ICI within 1 year. Patients diagnosed with AA had a steep decline in overall survival (OS) within the first 120 days; when compared to propensity score-matched patients without AA, they had a significantly worse OS (hazard ratio 1.72, 95% confidence interval 1.19-2.50; p = 0.003).
Topics: Humans; Anemia, Aplastic; Immune Checkpoint Inhibitors; Incidence; Databases, Factual; Electronic Health Records; Retrospective Studies
PubMed: 37455367
DOI: 10.1111/bjh.18985 -
British Journal of Haematology Dec 2009
Topics: Aged; Anemia, Aplastic; Autoimmune Diseases; Bone Marrow; Humans; Male; Paraneoplastic Syndromes; Thymectomy; Thymoma; Thymus Neoplasms
PubMed: 19438484
DOI: 10.1111/j.1365-2141.2009.07716.x